SCHEMBL4716178

SCHEMBL4716178

CCOC(=O)c1cc2[nH]c(=O)ccc2n1Cc1ccc(F)c(C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.47
ALDH1A1 P00352 4/20 0.47
POLB P06746 2/20 0.47
HTT P42858 1/20 0.47
KDM4E B2RXH2 5/20 0.46
TDP1 Q9NUW8 4/20 0.46
NPSR1 Q6W5P4 2/20 0.46
MAPK1 P28482 1/20 0.46
NOD2 Q9HC29 1/20 0.45
NOD1 Q9Y239 1/20 0.45
TSHR P16473 3/20 0.41
ATM Q13315 1/20 0.41
F10 P00742 3/20 0.41
PPARG P37231 1/20 0.41
RAB9A P51151 1/20 0.41
NCOA2 Q15596 1/20 0.41
NCOA1 Q15788 1/20 0.41
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4715652 0.90 MAPT (0.49) MAPTALDH1A1POLBHTTKDM4E
SCHEMBL4717121 0.84 MAPT (0.58) MAPTALDH1A1POLBHTTKDM4E
SCHEMBL4713786 0.83 MAPT (0.50) MAPTALDH1A1POLBKDM4ETDP1
SCHEMBL4715682 0.83 ALDH1A1 (0.51) MAPTALDH1A1POLBHTTKDM4E
SCHEMBL4715422 0.76 MAPT (0.48) MAPTALDH1A1POLBHTTKDM4E
SCHEMBL4716980 0.75 NOD2 (0.50) MAPTALDH1A1POLBHTTKDM4E
SCHEMBL4713175 0.73 MAPT (0.46) MAPTALDH1A1POLBHTTKDM4E
SCHEMBL4715544 0.73 NOD2 (0.48) MAPTALDH1A1POLBHTTKDM4E
SCHEMBL7678478 0.69 TSHR (0.61) MAPTALDH1A1POLBHTTKDM4E
SCHEMBL22760404 0.68 MAPT (0.57) MAPTALDH1A1POLBHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 MAPT 1831/4885ALDH1A1 3407/4885POLB 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.